Technical Analysis for CYCN - Cyclerion Therapeutics, Inc.

Grade Last Price % Change Price Change
F 1.80 -8.60% -0.17
CYCN closed down 8.6 percent on Wednesday, November 13, 2024, on 2.73 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Jack-in-the-Box Bearish Bearish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Expansion Breakdown Bearish Swing Setup -8.60%
Expansion Pivot Sell Setup Bearish Swing Setup -8.60%

   Recent Intraday Alerts

Alert Time
3x Volume Pace about 9 hours ago
Up 2% about 9 hours ago
Up 1% about 9 hours ago
2x Volume Pace about 12 hours ago
1.5x Volume Pace about 12 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cyclerion Therapeutics, Inc. Description

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion plans to advance its current portfolio of five differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are uniquely designed to target tissues of greatest relevance to the diseases they are intended to treat. These programs, each of which have important milestones in 2019, include olinciguat in Phase 2 development for sickle cell disease, praliciguat in Phase 2 trials for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy, IW-6463 in Phase 1 development for serious and orphan central nervous system diseases, and two late-stage discovery programs targeting serious liver and lung diseases, respectively.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Disease Organ Systems Pharmacology Kidney Disease Heart Failure Diabetic Nephropathy Cardiomyopathy Central Nervous System Disease Sickle Cell Disease Lung Diseases Orphan Disease

Is CYCN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.25
52 Week Low 1.71
Average Volume 19,181
200-Day Moving Average 2.89
50-Day Moving Average 2.72
20-Day Moving Average 2.70
10-Day Moving Average 2.52
Average True Range 0.41
RSI (14) 29.08
ADX 23.79
+DI 17.57
-DI 27.56
Chandelier Exit (Long, 3 ATRs) 2.90
Chandelier Exit (Short, 3 ATRs) 2.94
Upper Bollinger Bands 3.39
Lower Bollinger Band 2.00
Percent B (%b) -0.15
BandWidth 51.37
MACD Line -0.14
MACD Signal Line -0.04
MACD Histogram -0.1078
Fundamentals Value
Market Cap 4.4 Million
Num Shares 2.45 Million
EPS -18.53
Price-to-Earnings (P/E) Ratio -0.10
Price-to-Sales 7.25
Price-to-Book 0.70
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.16
Resistance 3 (R3) 2.19 2.10 2.10
Resistance 2 (R2) 2.10 2.01 2.08 2.08
Resistance 1 (R1) 1.95 1.95 1.90 1.92 2.06
Pivot Point 1.86 1.86 1.84 1.84 1.86
Support 1 (S1) 1.71 1.77 1.67 1.68 1.54
Support 2 (S2) 1.62 1.71 1.61 1.52
Support 3 (S3) 1.47 1.62 1.50
Support 4 (S4) 1.44